1. Home
  2. SER vs NEPH Comparison

SER vs NEPH Comparison

Compare SER & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

N/A

Current Price

$2.11

Market Cap

56.4M

Sector

Health Care

ML Signal

N/A

Logo Nephros Inc.

NEPH

Nephros Inc.

N/A

Current Price

$4.05

Market Cap

49.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SER
NEPH
Founded
2017
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.4M
49.4M
IPO Year
2024
2004

Fundamental Metrics

Financial Performance
Metric
SER
NEPH
Price
$2.11
$4.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
★ $15.00
$6.00
AVG Volume (30 Days)
★ 53.1K
17.9K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1000.00
EPS
N/A
★ 0.12
Revenue
$130,000.00
★ $18,789,000.00
Revenue This Year
N/A
$11.24
Revenue Next Year
N/A
$11.58
P/E Ratio
★ N/A
$35.25
Revenue Growth
★ 132.14
32.67
52 Week Low
$1.22
$2.66
52 Week High
$5.83
$6.42

Technical Indicators

Market Signals
Indicator
SER
NEPH
Relative Strength Index (RSI) 38.92 50.17
Support Level $1.69 $4.00
Resistance Level $2.29 $4.26
Average True Range (ATR) 0.23 0.26
MACD -0.04 -0.03
Stochastic Oscillator 11.54 27.96

Price Performance

Historical Comparison
SER
NEPH

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: